Medical Advisor - EM (Gr-MM)

Intas is a leading global pharmaceutical company dedicated to the development, manufacturing, and marketing of pharmaceutical formulations. Our mission is to address unmet medical and societal needs through a fully integrated pharmaceutical value chain that spans across the world. With a presence in over 85 countries, including major global markets like North America, Europe, Latin America, and the Asia-Pacific under the brand name Accord Healthcare, Intas has achieved rapid expansion through organic growth and strategic acquisitions. We uphold high standards of quality, with products approved by leading global regulatory agencies such as USFDA, MHRA, and EMA. Our substantial in-house R&D capability and focus on advanced areas like Biosimilars and New Chemical Entities demonstrate our commitment to excellence in healthcare. At Intas, our success is driven by the strength of our people. We are committed to attracting and retaining the best talent in the industry and fostering an empowering environment that encourages innovation and excellence. This ensures that every employee contributes significantly to both the company's growth and advancements in global healthcare. As a Medical Advisor - EM (Gr-MM) at Intas, you will be responsible for providing medical advisory support. Your role will involve (mention specific roles and responsibilities here). The ideal candidate for this position should have (mention required qualifications, skills, and industry experience). A background in (mention relevant professional/educational background) is preferred. (Any other requirements can be mentioned here). We offer competitive compensation and rewards for the right candidate. Location: Head Office, Ahmedabad, GJ, IN, 380054 Travel: 0% - 25% Join us at Intas Pharmaceuticals, where talent thrives and collaboration drives success. Our dynamic environment fosters individual potential and collective achievements. Diversity, innovation, and excellence are at the core of our values, allowing us to make significant strides in the pharmaceutical landscape. Date: 29 May 2025,